RCM
INSM icon

Raleigh Capital Management’s Insmed INSM Stock Holding History

Raleigh Capital Management’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4
Closed -$403 – 613
2025
Q2 		$403 Buy
+4
New +$306 ﹤0.01% 503
2025
Q1 		– Sell
-4
Closed -$276 – 791
2024
Q4 		$276 Buy
+4
New +$288 ﹤0.01% 974

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Raleigh Capital Management's INSM Position: Q3 2025 in Review

Raleigh Capital Management sold out of Insmed (INSM) in Q3 2025, closing a stake of 4 shares — an estimated $403 sold.

Raleigh Capital Management first reported a position in INSM in Q4 2024 and held it in 2 quarters. The position peaked at $403 in Q2 2025. 566 funds tracked by Wall St. Rank hold INSM as of Q3 2025.

  • Raleigh Capital Management reported no remaining Insmed position as of Q3 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 4 Insmed shares in Q3 2025, an estimated $403.
  • Raleigh Capital Management first reported a position in Insmed in Q4 2024 and held it in 2 quarters.
  • Raleigh Capital Management's Insmed position peaked at $403 in Q2 2025.
  • 566 funds tracked by Wall St. Rank held Insmed as of Q3 2025.

Based on Raleigh Capital Management's 13F filing for Q3 2025, filed 4 Nov 2025.